New scan could spot hidden myeloma earlier

NCT ID NCT06103838

Recruiting now Diagnosis Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 7 times

Summary

This phase 2 trial is testing whether a radioactive tracer called 18F-fluciclovine can detect multiple myeloma better than the standard FDG tracer during PET/CT scans. The study will enroll 60 adults with newly diagnosed or relapsed/refractory multiple myeloma. Each participant will receive both types of scans, along with optional MRI and bone marrow biopsies, to compare how well each tracer spots the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 18F-fluciclovine (a radioactive tracer injected for PET/CT imaging)
What this could lead to: If successful, this could lead to a more accurate imaging method for detecting multiple myeloma, especially when the disease returns, helping doctors start treatment earlier.
What could go wrong: This is an early phase 2 trial with only 60 participants, so results may not apply to everyone. The new tracer might not prove better than the current standard scan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.